Baxalta (BXLT) stock is rising on Monday after the companies announced this morning that Dublin-based bio-pharmaceutical company Shire will buy Baxalta for $32 billion in cash and stock.

Following suit is Takeda-owned Baxalta with 53 planned increases, and Belgian drugmaker UCB Pharma intends to raise prices on ...

Baxalta, which spun off from Baxter last summer but was immediately courted by Shire, made no comment on its website. Related stories: Pfizer to end $160bn merger with Allergan following US tax ...

With Shire offering to acquire Baxalta for more than $30 billion, we decided to check TheStreet Quant Ratings for stocks in the pharmaceuticals subsector that would be good investments. With Shire ...

Takeda-owned Baxalta announced the second-highest number of price increases, with 53 hikes planned so far, followed by Belgian drugmaker UCB Pharma, which intends to raise prices on 40 unique drugs.

The firm looked at spinoffs that created companies with a market value of more than $1 billion, including Baxter's spinoff of its Baxalta biopharma business and Kraft's spinoff of its snack ...

Drugmaker Shire is hoping to buy Baxalta, a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases. The London-listed group ...

Takeda inherited TAK-755 when it completed its acquisition of Shire, which in turn claimed ownership of the drug when it merged with original developer Baxalta in 2016. More than 1,000 people with ...

GR was a paid consultant to Cubist Pharmaceuticals on a previous project on "Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant pseudomonas aeruginosa ...

Genstar Capital, a leading private equity firm focused on investments in targeted segments of the healthcare, financial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The firm looked at spinoffs that created companies with a market value of more than $1 billion, including Baxter's spinoff of its Baxalta biopharma business and Kraft's spinoff of its snack ...